Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses peptide receptor radionuclide therapy and other new and exciting developments in the treatment of neuroendocrine tumors (NETs).
Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses peptide receptor radionuclide therapy and other new and exciting developments in the treatment of neuroendocrine tumors (NETs).
Transcript
What are some new and exciting trials/developments in the treatment of neuroendocrine tumors?
There are several exciting developments. In terms of clinical trials, I like to break it down according to the different drug classes. So, as for PRRT, or peptide receptor radionuclide therapy, I think we have a couple of exciting trials. One is a trial comparing PRRT to everolimus. I think it will be really helpful in telling us how to sequence therapy. Right now, we have everolimus, which is an active drug, we have PRRT, which certainly is a very active treatment. But, we don’t necessarily know how to best sequence or line these 2 drugs up. So, I think that will be an important trial to get done.
Another trial is a PRRT study looking at a somatostatin antagonist, which has a higher affinity for somatostatin receptor; it essentially sticks to it better than the agonist does with lutetium 177 radionuclide. So, that is a phase 2 study looking at tolerability and with efficacy as a secondary endpoint. I think that will be an important study, too. So, that’s what going on for PRRT.
In terms of other drugs, probably the most important trial right now is an ALLIANCE study. It’s a phase 3 study of cabozantinib versus placebo. So, there are very encouraging phase 2 data from cabozantinib in both small-bowel NETs and pancreatic NETs reported at GI ASCO almost 2 years ago. So, I think that is a very natural choice for a phase 3 study.
And then, there are some other earlier phase trials with interesting compounds. Some recognizing the somatostatin receptors, and others targeting different parts of the NET cell machinery.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More